Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14593926 | 0.80 | ELANE (0.36) | ELANEDGAT1CA1CA2CA7 | |
| SCHEMBL3082211 | 0.80 | TSHR (0.43) | ELANEDGAT1CA1CA2CA7 | |
| SCHEMBL4739516 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL4958194 | 0.78 | ELANE (0.35) | ELANEDGAT1CA1CA2CA7 | |
| Hydrogen Peroxide SCHEMBL22069984 | 0.78 | TSHR (0.42) | ELANEDGAT1CA1CA2CA7 | |
| Water SCHEMBL427934 | 0.78 | TSHR (0.42) | ELANEDGAT1CA1CA2CA7 | |
| SCHEMBL6009039 | 0.78 | ELANE (0.35) | ELANEDGAT1CA1CA2CA7 | |
| SCHEMBL12306266 | 0.76 | CA1 (0.37) | ELANEDGAT1CA1CA2CA7 | |
| SCHEMBL6897890 | 0.76 | CA1 (0.37) | ELANEDGAT1CA1CA2CA7 | |
| SCHEMBL6897035 | 0.76 | CA1 (0.37) | ELANEDGAT1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324273-B2 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2008079387-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | COMT, PARK7, DDT | ELANE 1079/4885DGAT1 2433/4885CA1 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.